title: Influence of DPYD Genetic Polymorphisms on 5-Fluorouracil Toxicities in Patients with Colorectal Cancer: A Meta-Analysis.
abstract: Our meta-analysis aggregated existing results from relevant studies to comprehensively investigate the correlations between genetic polymorphisms in dihydropyrimidine dehydrogenase (DPYD) gene and 5-fluorouracil (5-FU) toxicities in patients with colorectal cancer (CRC). The MEDLINE (1966∼2013), the Cochrane Library Database (Issue 12, 2013), EMBASE (1980∼2013), CINAHL (1982∼2013), Web of Science (1945∼2013), and the Chinese Biomedical Database (CBM) (1982∼2013) were searched without language restrictions. Meta-analyses were conducted with the use of STATA software (Version 12.0, Stata Corporation, College Station, TX, USA). Seven clinical cohort studies with a total of 946 CRC patients met our inclusion criteria, and NOS scores of each of the included studies were ≥5. Our findings showed that DPYD genetic polymorphisms were significantly correlated with high incidences of 5-FU-related toxicity in CRC patients. SNP-stratified analysis indicated that there were remarkable connections of IVS14+1G>A, 464T>A, and 2194G>A polymorphisms with the incidence of marrow suppression in CRC patients receiving 5-FU chemotherapy. Furthermore, we found that IVS14+1G>A, 496A>G, and 2194G>A polymorphisms were correlated with the incidence of gastrointestinal reaction. Ethnicity-stratified analysis also revealed that DPYD genetic polymorphisms might contribute to the development of marrow suppression and gastrointestinal reaction among Asians, but not among Caucasians. The present meta-analysis suggests that DPYD genetic polymorphisms may be correlated with the incidence of 5-FU-related toxicity in CRC patients.
authors.affiliation: Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China.
authors.forename: Qiang
authors.initials: Q
authors.lastname: Li
authors.affiliation: Department of Immunology, Laiwu Municipal Center for Disease Control & Prevention, Laiwu 271100, China.
authors.forename: Ying
authors.initials: Y
authors.lastname: Liu
authors.affiliation: Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China.
authors.forename: Hong-Mei
authors.initials: HM
authors.lastname: Zhang
authors.affiliation: Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China.
authors.forename: Yin-Peng
authors.initials: YP
authors.lastname: Huang
authors.affiliation: Department of Immunology, Laiwu Municipal Center for Disease Control & Prevention, Laiwu 271100, China.
authors.forename: Tian-Yi
authors.initials: TY
authors.lastname: Wang
authors.affiliation: Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China.
authors.forename: Dong-Sheng
authors.initials: DS
authors.lastname: Li
authors.affiliation: Department of Oncology, Jining No. 1 People's Hospital, No. 6 Jiankang Road, Jining, Shandong 272011, China.
authors.forename: Hong-Zhi
authors.initials: HZ
authors.lastname: Sun